ClinicalTrials.gg
RecruitingNCT06490250Updated Jun 15, 2025

Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients

An interventional study of Inspiratory Muscle Training and Baduanjin Exercise in Hypertrophic Cardiomyopathy and Heart Diseases, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to compare the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. By investigating these interventions, the investigators seek to introduce novel approaches that can enhance pulmonary function, exercise capacity, and overall quality of life for these patients.

In the study, which will involve three groups-the control group, the inspiratory muscle training (IMT) group, and the Baduanjin group-it was calculated that a total of 51 patients, with 17 in each group (n = 17), should be included.

The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other days.

The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.

Read the detailed description

Hypertrophic cardiomyopathy (HCM) is characterized by a left ventricular wall thickness exceeding 15 millimeters (mm), as assessed by echocardiography and cardiac magnetic resonance imaging (MRI). It is a common genetic heart disease worldwide, known to cause left ventricular outflow tract obstruction, mitral regurgitation, diastolic dysfunction, myocardial ischemia, arrhythmias, and autonomic dysfunction (PubMed identification number (ID): 29655825, 28912181, 24998133, 30110588, 33229115).

Many patients with HCM are asymptomatic, and the condition is often identified incidentally during routine screening. Symptomatic patients may experience dyspnea on exertion, chest pain, syncope, or presyncope (PubMed ID:11886323). Even when left ventricular systolic function is preserved, patients frequently develop symptoms such as dyspnea and fatigue, leading to exercise intolerance in the majority (PubMed ID:10913477).

HCM is a heterogeneous disease with a varied clinical course. In addition to these symptoms, patients may also face decreased exercise capacity and reduced quality of life (PubMed ID:19253387, 9326995). Furthermore, despite the well-established cardiovascular and overall health benefits of regular physical activity, many patients with HCM exhibit a high prevalence of physical inactivity (PubMed ID: 23340032, 27547438).

Studies on inspiratory muscle training have demonstrated its benefits in improving respiratory function, respiratory muscle strength, quality of life, and exercise capacity across various patient groups including chronic obstructive pulmonary disease, cystic fibrosis, spinal cord injury, and heart failure. It also helps alleviate symptoms of dyspnea and fatigue (PubMed ID:32209709, 30827470, 32936904, 31429207, 31937553). Additionally, inspiratory muscle training has been shown to enhance physical activity levels in different patient cohorts (PubMed ID: 17534784).

Research indicates that Baduanjin exercises can serve as a complementary and alternative treatment for cardiovascular patients, improving clinical outcomes and reducing adverse cardiovascular events (PubMed ID:30059552). Furthermore, studies have highlighted their positive effects on quality of life and exercise capacity in diverse populations such as healthy individuals and those with conditions like heart failure, Parkinson's disease, osteoarthritis, and chronic fatigue syndrome, while also mitigating fatigue symptoms (PubMed ID: 36436262, 19051349, 27627031, 23001463, 18315512, 26083663, 25610473, 27938498).

Based on existing literature, the investigators believe that inspiratory muscle training and Baduanjin exercises could potentially benefit patients with HCM by alleviating associated symptoms. However, there is a notable scarcity of studies investigating different exercise modalities in HCM patients. To the investigators' knowledge, no studies have specifically examined the effects of inspiratory muscle training or Baduanjin exercises in this population.

The study aims to fill this gap by being the first to compare the impacts of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with HCM. Through this research, the investigators seek to introduce new approaches that enhance pulmonary function, exercise capacity, and overall quality of life for these patients.

02

Conditions studied

  • Hypertrophic Cardiomyopathy
  • Heart Diseases

Keywords

  • Exercise capacity
  • Pulmonary function
  • Quality of life
03

In context

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

This study's planned enrollment of 51 is below the median of 60 across 182 interventional studies indexed under Cardiomyopathy, Hypertrophic.

Browse Cardiomyopathy, Hypertrophic studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
  • Clinically and hemodynamically stable (patients with Class I and II)
  • Patients over 18 years of age
  • Patients who provide

Exclusion criteria

Exclusion Criteria:

  • Acute decompensated heart failure
  • Decreased (\<40%)
  • Unstable angina pectoris
  • Significant coronary artery disease (CAD)
  • Severe renal dysfunction (estimated \<30 mL/min/m²)
  • Uncontrolled hypertension (despite medication)
  • Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
  • Severe neurological disorders causing autonomic dysfunction
  • Cognitive impairment that prevents communication
  • Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    Inspiratory Muscle Training (IMT) Group

    The inspiratory muscle training group will participate in the respiratory exercise program with the IMT device.

    Other: Inspiratory Muscle Training

  • Experimental
    Baduanjin Exercise Group

    The Baduanjin group will participate in the Baduanjin exercise program, which includes 8 movements.

    Other: Baduanjin Exercise

  • No intervention
    Control Group

    The control group will not receive any intervention.

Interventions

  • OtherInspiratory Muscle Training

    The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day

  • OtherBaduanjin Exercise

    The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.

06

What researchers measure

Primary outcomes

  1. The Six-Minute Walk Test (6MWT)

    Distance walked in six minutes will be recorded. Test will be conducted according to the guideline of American Thoracic Society. Functional exercise capacity will be evaluated with the six-minute walk test. Patients will be walked in a 30-meter-long corridor for 6 minutes and the maximum walking distance will be measured. Before and after the test, heart rate, blood pressure and O2 saturation will be measured with pulse oximetry, and dyspnea and fatigue levels will be determined according to the Modified Borg scale.

    Time frame: Change from Baseline at 8 weeks

Secondary outcomes

  1. Pulmonary Function Tests (PFT)

    Pulmonary function tests will be conducted using a spirometer, following the American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria.

    Time frame: Change from Baseline at 8 weeks

  2. Maximal Inspiratory Pressure (MIP)

    Inspiratory muscle strength will be measured using a portable electronic oral pressure measurement device (MicroRPM; Micro Medical, UK). According to the recommendations of the American Thoracic Society and the European Respiratory Society, a maximum of five maneuvers will be performed, with 1-minute intervals between them. For maximum inspiratory pressure (MIP) measurement, patients will be seated and will first exhale maximally using a nose clip, then be asked to inhale maximally through a mouthpiece for at least 2 seconds. The results will be recorded in centimetres of water (cmH2O) and as a percentage of the expected value. Maneuvers will be considered satisfactory when a change of less than 10% is observed between three measurements, and the highest value will be recorded.

    Time frame: Change from Baseline at 8 weeks

  3. Nitric Oxide Levels

    Nitric oxide levels' measurements will be performed with a fractional exhaled nitric oxide (FeNO) device.

    Time frame: Change from Baseline at 8 weeks

  4. Minnesota Living with Heart Failure Questionnaire

    The Minnesota Living with Heart Failure Questionnaire will be used to assess the quality of life. This questionnaire evaluates how much heart failure has affected the patient's life over the past month (4 weeks). Patients circle a number from 0 to 5 next to each question to indicate the impact on their life, with 0 meaning no impact. The survey consists of 21 questions.

    Time frame: Change from Baseline at 8 weeks

  5. New York Heart Association (NYHA) Classification

    The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity; the limitations/symptoms are in regards to normal breathing and varying degrees in shortness of breath and or angina pain.

    Time frame: Change from Baseline at 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail. 2018 May;6(5):364-375. doi: 10.1016/j.jchf.2018.02.010. Epub 2018 Apr 11. PubMed 29655825 ↗
  • Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):749-770. doi: 10.1161/CIRCRESAHA.117.311059. PubMed 28912181 ↗
  • Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014 Jul 8;64(1):83-99. doi: 10.1016/j.jacc.2014.05.003. PubMed 24998133 ↗
  • Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018 Aug 16;379(7):655-668. doi: 10.1056/NEJMra1710575. No abstract available. PubMed 30110588 ↗
  • Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055. doi: 10.1016/j.jacc.2020.08.044. Epub 2020 Nov 20. PubMed 33229115 ↗
  • Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. PubMed 11886323 ↗
  • Sharma S, Elliott P, Whyte G, Jones S, Mahon N, Whipp B, McKenna WJ. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000 Jul 15;86(2):162-8. doi: 10.1016/s0002-9149(00)00854-7. PubMed 10913477 ↗
  • Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A. 2009 Feb 15;149A(4):602-12. doi: 10.1002/ajmg.a.32710. PubMed 19253387 ↗
  • Cox S, O'Donoghue AC, McKenna WJ, Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997 Aug;78(2):182-7. doi: 10.1136/hrt.78.2.182. PubMed 9326995 ↗
  • Reineck E, Rolston B, Bragg-Gresham JL, Salberg L, Baty L, Kumar S, Wheeler MT, Ashley E, Saberi S, Day SM. Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. Am J Cardiol. 2013 Apr 1;111(7):1034-9. doi: 10.1016/j.amjcard.2012.12.018. Epub 2013 Jan 19. PubMed 23340032 ↗
  • Sweeting J, Ingles J, Timperio A, Patterson J, Ball K, Semsarian C. Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. Open Heart. 2016 Jul 20;3(2):e000484. doi: 10.1136/openhrt-2016-000484. eCollection 2016. PubMed 27547438 ↗
  • Figueiredo RIN, Azambuja AM, Cureau FV, Sbruzzi G. Inspiratory Muscle Training in COPD. Respir Care. 2020 Aug;65(8):1189-1201. doi: 10.4187/respcare.07098. Epub 2020 Mar 24. PubMed 32209709 ↗
  • Zeren M, Cakir E, Gurses HN. Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial. Respir Med. 2019 Mar;148:24-30. doi: 10.1016/j.rmed.2019.01.013. Epub 2019 Jan 28. PubMed 30827470 ↗
  • Azambuja ACM, de Oliveira LZ, Sbruzzi G. Inspiratory Muscle Training in Patients With Heart Failure: What Is New? Systematic Review and Meta-Analysis. Phys Ther. 2020 Dec 7;100(12):2099-2109. doi: 10.1093/ptj/pzaa171. PubMed 32936904 ↗
  • Hossein Pour AH, Gholami M, Saki M, Birjandi M. The effect of inspiratory muscle training on fatigue and dyspnea in patients with heart failure: A randomized, controlled trial. Jpn J Nurs Sci. 2020 Apr;17(2):e12290. doi: 10.1111/jjns.12290. Epub 2019 Aug 19. PubMed 31429207 ↗
  • Boswell-Ruys CL, Lewis CRH, Wijeysuriya NS, McBain RA, Lee BB, McKenzie DK, Gandevia SC, Butler JE. Impact of respiratory muscle training on respiratory muscle strength, respiratory function and quality of life in individuals with tetraplegia: a randomised clinical trial. Thorax. 2020 Mar;75(3):279-288. doi: 10.1136/thoraxjnl-2019-213917. Epub 2020 Jan 14. PubMed 31937553 ↗
  • Aznar-Lain S, Webster AL, Canete S, San Juan AF, Lopez Mojares LM, Perez M, Lucia A, Chicharro JL. Effects of inspiratory muscle training on exercise capacity and spontaneous physical activity in elderly subjects: a randomized controlled pilot trial. Int J Sports Med. 2007 Dec;28(12):1025-9. doi: 10.1055/s-2007-965077. Epub 2007 May 29. PubMed 17534784 ↗
  • Xiao X, Wang J, Gu Y, Cai Y, Ma L. Effect of community based practice of Baduanjin on self-efficacy of adults with cardiovascular diseases. PLoS One. 2018 Jul 30;13(7):e0200246. doi: 10.1371/journal.pone.0200246. eCollection 2018. PubMed 30059552 ↗
  • Yang WY, Xu Y, Ye L, Rong LJ, Feng J, Huang BL, Chien CW, Tung TH. Effects of Baduanjin exercise on quality-of-life and exercise capacity in patients with heart failure: A systematic review and meta-analysis. Complement Ther Clin Pract. 2023 Feb;50:101675. doi: 10.1016/j.ctcp.2022.101675. Epub 2022 Oct 28. PubMed 36436262 ↗
  • Hsu MC, Wang TS, Liu YP, Liu CF. Effects of Baduanjin exercise on oxidative stress and antioxidant status and improving quality of life among middle-aged women. Am J Chin Med. 2008;36(5):815-26. doi: 10.1142/S0192415X08006260. PubMed 19051349 ↗
  • Xiao C, Zhuang Y, Kang Y. Effect of Health Qigong Baduanjin on Fall Prevention in Individuals with Parkinson's Disease. J Am Geriatr Soc. 2016 Nov;64(11):e227-e228. doi: 10.1111/jgs.14438. Epub 2016 Sep 14. No abstract available. PubMed 27627031 ↗
  • An BC, Wang Y, Jiang X, Lu HS, Fang ZY, Wang Y, Dai KR. Effects of Baduanjin () exercise on knee osteoarthritis: a one-year study. Chin J Integr Med. 2013 Feb;19(2):143-8. doi: 10.1007/s11655-012-1211-y. Epub 2012 Sep 21. PubMed 23001463 ↗
  • An B, Dai K, Zhu Z, Wang Y, Hao Y, Tang T, Yan H. Baduanjin alleviates the symptoms of knee osteoarthritis. J Altern Complement Med. 2008 Mar;14(2):167-74. doi: 10.1089/acm.2007.0600. PubMed 18315512 ↗
  • Liao Y, Lin Y, Zhang C, Xue XL, Mao QX, Zhang Y, Dai JG, Wang TF. Intervention Effect of Baduanjin Exercise on the Fatigue State in People with Fatigue-Predominant Subhealth: A Cohort Study. J Altern Complement Med. 2015 Sep;21(9):554-62. doi: 10.1089/acm.2014.0395. Epub 2015 Jun 17. PubMed 26083663 ↗
  • Chan JS, Ho RT, Chung KF, Wang CW, Yao TJ, Ng SM, Chan CL. Qigong exercise alleviates fatigue, anxiety, and depressive symptoms, improves sleep quality, and shortens sleep latency in persons with chronic fatigue syndrome-like illness. Evid Based Complement Alternat Med. 2014;2014:106048. doi: 10.1155/2014/106048. Epub 2014 Dec 25. PubMed 25610473 ↗
  • Chan JS, Li A, Ng SM, Ho RT, Xu A, Yao TJ, Wang XM, So KF, Chan CL. Adiponectin Potentially Contributes to the Antidepressive Effects of Baduanjin Qigong Exercise in Women With Chronic Fatigue Syndrome-Like Illness. Cell Transplant. 2017 Mar 13;26(3):493-501. doi: 10.3727/096368916X694238. Epub 2016 Dec 7. PubMed 27938498 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jul 2025, 9 months after the start.

Of 47 non-industry interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 9 months is below that.

Counting every sponsor, half of 52 studies reached it within 52 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2024
First posted
Jul 8, 2024
StartActual
Oct 25, 2024
Primary completionEst.
Jul 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06490250
Responsible party
Muhammed Yurtseven (PhD Student, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Jul 8, 2024
Start date
Oct 25, 2024
Primary completion
Jul 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Jun 15, 2025

Study contacts

Rengin Demir, Prof
Contact
rengindemir@yahoo.com
+902124592000 ext. 50114
Veysel Oktay, Assoc Prof
Contact
drvoktay@gmail.com
+902124592000 ext. 50114
Rengin Demir, Prof
study director · Istanbul University-Cerrahpasa (IUC) Cardiology Institute
Veysel Oktay, Assoc Prof
study chair · Istanbul University-Cerrahpasa (IUC) Cardiology Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion